SRPT

Sarepta Therapeutics, Inc. [SRPT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SRPT Stock Summary

Top 10 Correlated ETFs

SRPT


Top 10 Correlated Stocks

SRPT


In the News

08:00 28 Mar 2024 SRPT

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

Regenxbio reported some favorable data from a phase 1 clinical trial. Sarepta Therapeutics has a medicine on the market for the same target.

05:45 28 Mar 2024 SRPT

Got $1,000? Buy These Hot Growth Stocks Before They Take Off.

Biopharma company Sarepta Therapeutics is on the verge of reaching sustained profits. Last year was miserable for Enphase Energy, and this year isn't likely to be much better thanks to the tepid demand for residential solar solutions.

09:47 28 Mar 2024 SRPT

Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst

Sarepta Therapeutics is trying to widen its market for Elevidys. Regulators should deliver a verdict in early March.

01:36 28 Mar 2024 SRPT

Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

07:33 28 Mar 2024 SRPT

Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript

07:01 28 Mar 2024 SRPT

Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

07:15 28 Mar 2024 SRPT

Is It Too Late to Buy Sarepta Therapeutics Stock?

Sarepta Therapeutics faced some issues last year, but it earned approval for an important medicine. The biotech is on the verge of another key regulatory nod that should help improve its financial results.

09:51 28 Mar 2024 SRPT

Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

12:25 28 Mar 2024 SRPT

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.

08:30 28 Mar 2024 SRPT

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 28, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2023 financial results and to provide a corporate update. The event will be webcast live under the investor relati.

SRPT Financial details

Company Rating
Strong Buy
Market Cap
11.97B
Income
-535.98M
Revenue
1.24B
Book val./share
8.14
Cash/share
15.87
Dividend
-
Dividend %
-
Employees
1.31K
Optionable
Yes
Shortable
Yes
Earnings
30 Apr 2024
P/E
-15.41
Forward P/E
11.42
PEG
5.21
P/S
10.14
P/B
13.93
P/C
8.12
P/FCF
-18.22
Quick Ratio
4.63
Current Ratio
5.44
Debt / Equity
1.46
LT Debt / Equity
1.32
-
-
EPS (TTM)
-6.1
EPS next Y
11.28
EPS next Q
-0.03
EPS this Y
-33.03%
EPS next Y
-284.85%
EPS next 5Y
-292.03%
EPS last 5Y
-9.79%
Revenue last 5Y
26.7%
Revenue Q/Q
19.58%
EPS Q/Q
-206.52%
-
-
-
-
SMA20
-3.76%
SMA50
11.3%
SMA100
42.22%
Inst Own
61.14%
Inst Trans
0.67%
ROA
-22%
ROE
-106%
ROC
-0.15%
Gross Margin
88%
Oper. Margin
-36%
Profit Margin
-63%
Payout
-
Shs Outstand
93.86M
Shs Float
88.24M
-
-
-
-
Target Price
148.67
52W Range
55.25-159.89
52W High
-18.99%
52W Low
+134.19%
RSI
58
Rel Volume
0.14
Avg Volume
1.11M
Volume
159.64K
Perf Week
2.16%
Perf Month
3.13%
Perf Quarter
3.93%
Perf Half Y
12.26%
-
-
-
-
Beta
0.933
-
-
Volatility
1.68%, 5.75%
Prev Close
-1.09%
Price
128.805
Change
-0.34%

SRPT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
5.176.938.6411.4813.46
Net income per share
-9.71-7.11-5.15-8.66-5.8
Operating cash flow per share
-6.21.38-5.45-4-5.42
Free cash flow per share
-7.050.32-5.93-4.38-6.37
Cash per share
15.2824.8726.0424.4818.14
Book value per share
11.119.7711.424.749.3
Tangible book value per share
10.949.611.244.648.98
Share holders equity per share
11.119.7711.424.749.3
Interest debt per share
10.4317.0218.1320.5613.83
Market cap
9.5B13.29B7.32B10.53B8.91B
Enterprise value
9.39B12.86B6.34B11.18B9.88B
P/E ratio
-13.28-23.98-17.47-14.97-16.62
Price to sales ratio
24.9424.610.4311.297.17
POCF ratio
-20.81123.64-16.51-32.37-17.78
PFCF ratio
-18.3525.94-15.19-29.56-15.14
P/B Ratio
11.6117.447.8927.3510.37
PTB ratio
11.6117.447.8927.3510.37
EV to sales
24.6723.819.0311.987.95
Enterprise value over EBITDA
-20.01-24.29-15.38-23.61-36.88
EV to operating cash flow
-20.58119.64-14.31-34.36-19.72
EV to free cash flow
-18.09508.93-13.16-31.39-16.79
Earnings yield
-0.08-0.04-0.06-0.07-0.06
Free cash flow yield
-0.050-0.07-0.03-0.07
Debt to equity
0.91.661.524.21.46
Debt to assets
0.40.420.450.520.38
Net debt to EBITDA
0.220.812.37-1.37-3.62
Current ratio
5.555.975.754.133.95
Interest coverage
-17.03-9.41-7.08-10.07-12.17
Income quality
0.64-0.191.060.460.93
Dividend Yield
0.030.02000
Payout ratio
-0.34-0.52000
Sales general and administrative to revenue
0.750.590.40.480.39
Research and developement to revenue
1.471.341.10.940.71
Intangibles to total assets
0.010000.01
Capex to operating cash flow
0.14-0.760.090.090.17
Capex to revenue
-0.16-0.15-0.05-0.03-0.07
Capex to depreciation
-2.05-3.05-1.01-0.74-1.48
Stock based compensation to revenue
0.210.20.160.250.15
Graham number
49.2939.5436.3930.3834.84
ROIC
-0.33-0.27-0.19-0.26-0.12
Return on tangible assets
-0.39-0.19-0.13-0.23-0.17
Graham Net
3.75-0.831.45-5.63-2.57
Working capital
1.2B2.07B2.15B1.94B1.93B
Tangible asset value
805.69M748.13M913.77M377.37M829.72M
Net current asset value
464.28M262.24M384.13M-185.56M174.09M
Invested capital
0.91.661.524.21.46
Average receivables
71.49M116.26M155.11M215.67M349.7M
Average payables
50.96M89.59M93.92M86.31M130.4M
Average inventory
148.41M201.67M209.09M195.09M263.41M
Days sales outstanding
90.0393.6589.26101.59129.08
Days payables outstanding
439.23639.74288.62249.98400.38
Days of inventory on hand
1.11K1.34K700.34531.82783.83
Receivables turnover
4.053.94.093.592.83
Payables turnover
0.830.571.261.460.91
Inventory turnover
0.330.270.520.690.47
ROE
-0.87-0.73-0.45-1.83-0.62
Capex per share
-0.85-1.05-0.47-0.38-0.95

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.182.872.953.733.76
Net income per share
-1.34-5.86-0.27-0.460.43
Operating cash flow per share
-1.14-2.37-1.38-1.29-0.52
Free cash flow per share
-1.23-2.48-1.58-1.75-0.7
Cash per share
24.4821.3420.9919.515.87
Book value per share
4.748.088.368.68.14
Tangible book value per share
4.6488.168.387.86
Share holders equity per share
4.748.088.368.68.14
Interest debt per share
19.9914.6819.1419.1111.73
Market cap
10.53B12.15B10.15B10.78B10.18B
Enterprise value
11.18B12.57B10.67B11.6B11.15B
P/E ratio
-24.1-5.88-106.04-65.855.76
Price to sales ratio
40.7547.9538.8732.4725.66
POCF ratio
-113.97-58.04-83.07-93.94-186.3
PFCF ratio
-104.93-55.53-72.46-69.24-138.17
P/B Ratio
27.3517.0513.714.111.85
PTB ratio
27.3517.0513.714.111.85
EV to sales
43.2649.5940.8334.9728.1
Enterprise value over EBITDA
-137.2-116.66-105.23929.64-391.81
EV to operating cash flow
-121.01-60.03-87.27-101.17-204.01
EV to free cash flow
-111.41-57.43-76.11-74.57-151.31
Earnings yield
-0.01-0.04000
Free cash flow yield
-0.01-0.02-0.01-0.01-0.01
Debt to equity
4.21.812.282.221.46
Debt to assets
0.520.420.540.540.38
Net debt to EBITDA
-7.98-3.87-5.0666.46-34.03
Current ratio
4.134.634.965.443.95
Interest coverage
-15.97-21.84-25.56-3.99-1.47
Income quality
0.850.415.112.8-1.2
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.470.440.450.360.88
Research and developement to revenue
0.830.970.930.590.49
Intangibles to total assets
000.010.010.01
Capex to operating cash flow
0.090.050.150.360.35
Capex to revenue
-0.03-0.04-0.07-0.12-0.05
Capex to depreciation
-0.75-0.84-1.66-3.74-1.25
Stock based compensation to revenue
0.20.160.180.140.12
Graham number
11.9732.647.139.448.9
ROIC
-0.06-0.07-0.09-0.010.01
Return on tangible assets
-0.04-0.17-0.01-0.010.01
Graham Net
-5.63-1.67-2.37-2.52-2.25
Working capital
1.94B1.95B1.97B2B1.93B
Tangible asset value
377.37M705.55M723.39M744.86M829.72M
Net current asset value
-185.56M141.34M88.14M105.5M174.09M
Invested capital
4.21.812.282.221.46
Average receivables
241.57M273.89M277.62M310.71M396.98M
Average payables
107.17M101.29M108.25M98.87M126.43M
Average inventory
212.58M203.32M214.78M235.44M283.44M
Days sales outstanding
90.44102.2892.0496.0999.74
Days payables outstanding
280.16274.26289.58213.78335.99
Days of inventory on hand
596.03520.91598.37593.12657.76
Receivables turnover
10.880.980.940.9
Payables turnover
0.320.330.310.420.27
Inventory turnover
0.150.170.150.150.14
ROE
-0.28-0.73-0.03-0.050.05
Capex per share
-0.1-0.11-0.2-0.46-0.18

SRPT Frequently Asked Questions

What is Sarepta Therapeutics, Inc. stock symbol ?

Sarepta Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol SRPT

Is Sarepta Therapeutics, Inc. buy or a sell ?

18 stock analysts have 18 predictions with a medium analyst target price of $137.11. The lowest prediction is $80 and the highest is $187

What is SRPT stock prediction ?

What is Sarepta Therapeutics, Inc. stock quote today ?

Sarepta Therapeutics, Inc. stock price is $128.805 today.

Is Sarepta Therapeutics, Inc. stock public?

Yes, Sarepta Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap